{"page_content": "ESG Report 2023\nAt a Glance\nFIRST AND ONLY DISEASE-MODIFYING THERAPY FOR PK DEFICIENCY  \nAPPROVED IN THE U.S., EU, AND GREAT BRITAIN\n2022FOUNDED \n2008HEADQUARTERS\nCambridge, Mass.1ST APPROVED THERAPIES\n2017 & 2018PK ACTIVATION PROGRAMS\nPyruvate Kinase Deficiency, \nThalassemia & Sickle Cell Disease, \nLower-Risk Myelodysplastic SyndromesWe are expanding our impact.\nOur pioneering research in PK \nactivation has yielded the first approved therapy for a rare, debilitating, lifelong blood disorder as well as a robust clinical and preclinical pipeline.We were founded to unlock a new field \nof discovery in cellular metabolism. \nOur first application in IDH inhibition \nresulted in two precision oncology therapies within 10 years. We are fueled by     \n       connections.  \nAgios is a biopharmaceutical company passionately committed to improving the lives of people living with rare diseases. \nThe strong bonds we build with patient \ncommunities, healthcare professionals, partners and colleagues enrich the impact we have as experts in cellular metabolism. These connections enhance our collaboration, creativity  \nand productivity  \u2014 driving our ability  \nto develop life-changing treatments.\n5", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 4, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}